Kelun Industry Group’s lenvatinib generic drug application approved by CDE

On May 11, Kelun Industry Group’s Lenvatinib Mesylate Capsule 4 generic drug application was approved by CDE.
According to data from Menet.com, the original ground medicine (OGM) lenvatinib mesylate capsules were approved to enter the domestic market in September 2018. Its sales in China’s public medical institutions are close to 240 million yuan in 2019.

On May 11, Kelun Industry Group’s Lenvatinib Mesylate Capsule 4 generic drug application was approved by CDE.

According to data from Menet.com, the original ground medicine (OGM) lenvatinib mesylate capsules were approved to enter the domestic market in September 2018. Its sales in China’s public medical institutions are close to 240 million yuan in 2019.

At present, there are no generic drugs for it on the domestic market.

Lenvatinib mesylate capsules are first-line treatments for liver cancer and are suitable for patients with unresectable hepatocellular carcinoma who have not previously received systemic systemic treatment.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/12/kelun-industry-group-s-lenvatinib-generic-drug-application-approved-by-cde/.

Leave a Reply

Please Login to Comment